Lupin gets USFDA nod to market generic anti-bacterial drug
New Delhi: Drug maker Lupin Ltd on Wednesday said it has received US health regulator’s nod to market generic version of Flagyl tablets, a drug used to treat bacterial infections, in the American market.
The company has received final approval from the US Food and Drug Administration (US FDA) to market metronidazole tablets in strengths of 250 mg and 500 mg, Lupin said in a statement.
The Mumbai-based company’s product is a generic version of G.D. Searle LLC’s Flagyl tablets which are indicated in the treatment of a wide variety of bacterial infections.
As per IMS MAT sales June data, Flagyl tablets had sales of $44.1 million in the US market. Lupin shares on Wednesday closed 1.39% up at Rs995 per scrip on BSE.
- Ford sees big opportunity for smart mobility services in India
- Irdai panel to help move to risk-based capital norms in 3 years
- LTCG case: Sebi revokes trading ban on 14 entities
- Bangladesh imposes mobile phone ban on Rohingya refugees
- Govt to set up 5 scrap-based steel plants with Rs500 crore investment